GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cellev8 Nutrition CELV · USD

N/A · US listing · 🇺🇸 United States

Compare

0.07

-0.38%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2010

Net income

−$106,900

FY2010FY2010

Free cash flow

−$6,300

FY2010FY2010

Shareholders' equity

−$382,600

FY2010FY2010

Income statement

Fiscal years

FY2010
Research and development$55,200
Operating income−$105,400
Net income−$106,900
Diluted earnings per share-0.96

Balance sheet

At each fiscal year end

FY2010
Total liabilities$382,600
Shareholders' equity−$382,600
Shares outstanding0m

Cash flow

Fiscal years

FY2010
Cash from operations−$6,300
Free cash flow−$6,300

Latest quarters

By quarter end

Aug 2011May 2011Feb 2011Nov 2010Aug 2010
Operating income−$21,100−$16,400−$31,900−$20,000−$1,900
Net income−$21,300−$17,200−$32,400−$20,800−$2,400
Diluted earnings per share-0.19-0.15-0.29-0.19-0.02
Total assets$100$100$100——
Cash and short-term investments$100$100$100——
Shareholders' equity−$470,500−$453,700−$435,300−$382,600−$349,300

Growth per year

Compound annual rate

3 years5 years10 years
Operating income541.1%——
Net income544.1%——

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-66%80589%53%48%81718%2277%1875%3864%-21%41%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 235-to-1 reverse split · 20 Jun 2014
  • 2-for-1 split · 3 Apr 2008

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.